Per Google AI
“AD109 combines two established medications into a single, fixed-dose tablet:
Atomoxetine: A selective norepinephrine reuptake inhibitor (NRI) that activates upper airway dilator muscles.
Aroxybutynin: A novel antimuscarinic agent that prevents the airway from sagging or collapsing during sleep.
Clinical Trial Results
AD109 has completed large Phase 3 clinical trials (including the SynAIRgy and LunAIRo studies), which showed highly promising results across a broad range of patient weights and OSA severities:
Patients taking AD109 experienced a 44% to 47% reduction in the Apnea-Hypopnea Index (AHI)—the primary measure of breathing interruptions—compared to roughly 6% to 18% for those on a placebo.
Over 40% of patients saw their disease severity category improve, and nearly 23% achieved complete disease control (fewer than 5 events per hour).
Meaningful improvements were also observed in blood oxygen levels and oxygen desaturation.
I find it interesting that the drug given in the study includes Norepinephrine (also called noradrenaline). An organic chemical that acts both as a stress hormone and a brain neurotransmitter. It plays a critical role in your body’s “fight-or-flight” response by increasing alertness, boosting heart rate, and constricting blood vessels to elevate blood pressure.
High levels can lead to severe anxiety, hyperarousal, and high blood pressure.